Related content

Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer

By Chitapanarux I.   Tonusin A.   Sukthomya V.   Charuchinda C.   Pukanhapan N.   Lorvidhaya V.  

Gynecologic Oncology, Vol. 89, Iss. 3, 2003-06 ,pp. : 402-407

Elsevier

Access to resources Recommend Favorite

Raltitrexed plus weekly oxaliplatin as first-line chemotherapy in metastatic colorectal cancer: A multicenter non-randomized phase II study

By Santini Daniele   Massacesi Cristian   D’Angelillo Rolando   Marcucci Fabiana   Campisi Costantino   Vincenzi Bruno   Pilone Alberta   Bianco Vincenzo   Bonsignori Maurizio   Tonini Giuseppe  

Medical Oncology, Vol. 21, Iss. 1, 2004-03 ,pp. : 59-66

Humana Press, Inc

Access to resources Recommend Favorite

Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer

By Kalmadi Sujith   McNeill Giles   Davis Mellar   Peereboom David   Adelstein David   Mekhail Tarek  

Medical Oncology, Vol. 23, Iss. 4, 2006-12 ,pp. : 507-513

Humana Press, Inc

Access to resources Recommend Favorite

Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer

By Cassinello J.   López-Alvarez P.   Martínez-Guisado A.   Valladares M.   Huidobro G.   López R.   Bohn U.   Sevilla I.   Ballesteros P.   Jorge M.   Pérez-Carrión R.   Fernández J.   Dorta J.  

Medical Oncology, Vol. 20, Iss. 1, 2003-03 ,pp. : 37-43

Humana Press, Inc

Access to resources Recommend Favorite

Excess Toxicity Associated with Docetaxel and Irinotecan in Patients with Metastatic, Gemcitabine-Refractory Pancreatic Cancer: Results of a Phase II Study

By Ko Andrew   Dito Elizabeth   Schillinger Brian   Venook Alan   Bergsland Emily   Tempero Margaret  

Cancer Investigation, Vol. 26, Iss. 1, 2007-12 ,pp. : 47-52

Informa Healthcare

Access to resources Recommend Favorite